Drug Profile
CT 413
Alternative Names: CT413Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator HEC Pharm
- Class Antineoplastics; Small molecules
- Mechanism of Action Axl receptor tyrosine kinase inhibitors; Proto-oncogene protein c-mer inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for preclinical development in Solid-tumours in China
- 27 Mar 2020 CT 413 is still in preclinical development in Solid-tumours in China (HEC Pharm pipeline March 2020)